{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:43:18Z","timestamp":1785825798065,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","award":["20240093"],"award-info":[{"award-number":["20240093"]}],"id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","award":["20240798"],"award-info":[{"award-number":["20240798"]}],"id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118158","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:29:41Z","timestamp":1781245781000},"page":"118158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["RRBP1 promotes osimertinib resistance by activating fatty acid oxidation-dependent metabolic and immune reprogramming in EGFR-Mutant lung adenocarcinoma"],"prefix":"10.1016","volume":"251","author":[{"given":"Yajie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4986-4240","authenticated-orcid":false,"given":"Yaozhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118158_b0005","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/ijms26052049","article-title":"Lung Cancer\u2014Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"IJMS"},{"key":"10.1016\/j.bcp.2026.118158_b0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11523-018-0554-5","article-title":"Treatment of EGFR T790M-positive Non-Small Cell Lung Cancer","volume":"13","author":"Choo","year":"2018","journal-title":"Targ. Oncol."},{"key":"10.1016\/j.bcp.2026.118158_b0015","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jtho.2016.06.032","article-title":"Acquired Resistance to First-Line Afatinib and the challenges of Prearranged Progression Biopsies","volume":"11","author":"Campo","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2026.118158_b0020","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an Irreversible EGFR TKI, Overcomes T790M-mediated Resistance to EGFR Inhibitors in Lung Cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118158_b0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118158_b0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118158_b0035","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-02675-8","article-title":"Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance","volume":"42","author":"Xiao","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bcp.2026.118158_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106805","article-title":"Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip","volume":"199","author":"Tan","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2026.118158_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-022-02509-x","article-title":"Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis","volume":"22","author":"Wan","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.118158_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.007","article-title":"Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer","volume":"189","author":"Han","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118158_b0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and Metabolism in the Tumor Microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118158_b0060","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","article-title":"Metabolic Regulation of Macrophage Polarization in Cancer","volume":"5","author":"Mehla","year":"2019","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.bcp.2026.118158_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01547-3","article-title":"Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR\/Src\/Erk\/SP1 signaling-mediated ERR\u03b1 re-expression","volume":"21","author":"Pan","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.118158_b0070","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1038\/s41388-021-02057-0","article-title":"Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118158_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2022.101198","article-title":"Endoplasmic reticulum stress and lipids in health and diseases","volume":"89","author":"Celik","year":"2023","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bcp.2026.118158_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114613","article-title":"Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC","volume":"43","author":"Li","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2026.118158_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002548","article-title":"S100A4 enhances protumor macrophage polarization by control of PPAR-\u03b3-dependent induction of fatty acid oxidation","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118158_b0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/2159-8290.CD-21-0316","article-title":"Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118158_b0095","doi-asserted-by":"crossref","first-page":"81598","DOI":"10.18632\/oncotarget.13150","article-title":"Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975\/OSIR cell line","volume":"7","author":"Tang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118158_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193601","article-title":"The phorbol 12-myristate-13-acetate differentiation protocol is critical to the interaction of THP-1 macrophages with Salmonella Typhimurium","volume":"13","author":"Starr","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118158_b0105","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.cmet.2018.09.018","article-title":"Fatty Acid Oxidation in Macrophages and T Cells: Time for Reassessment?","volume":"28","author":"Van den Bossche","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118158_b0110","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.21037\/tlcr-24-881","article-title":"Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study","volume":"14","author":"Auclin","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bcp.2026.118158_b0115","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2025.06.030","article-title":"Lazertinib Versus Osimertinib in previously Untreated EGFR-Mutant Advanced NSCLC: a Randomized, Double-blind, Exploratory Analysis from MARIPOSA","volume":"20","author":"Lee","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2026.118158_b0120","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.jtho.2025.06.007","article-title":"Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer","volume":"20","author":"Fukuda","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2026.118158_b0125","article-title":"Impact of Baseline \u03b2-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer","volume":"9","author":"Kulhavy","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.bcp.2026.118158_b0130","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s12672-025-02529-9","article-title":"Integrative bulk RNA analysis unveils immune evasion mechanisms and predictive biomarkers of osimertinib resistance in non-small cell lung cancer","volume":"16","author":"Shi","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bcp.2026.118158_b0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1615\/CritRevOncog.2024053830","article-title":"Polarization of M2 Tumor-Associated Macrophages (TAMs) in Cancer Immunotherapy","volume":"29","author":"Bui","year":"2024","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.bcp.2026.118158_b0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1546-9","article-title":"M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide","volume":"15","author":"Genin","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118158_b0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13046-025-03490-9","article-title":"Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"44","author":"Liu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118158_b0150","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.31557\/APJCP.2025.26.8.2855","article-title":"Matairesinol Targets Lipid Metabolism Reprogramming in AR-Independent Prostate Cancer Cells","volume":"26","author":"Mahajan","year":"2025","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bcp.2026.118158_b0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008811","article-title":"Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118158_b0160","doi-asserted-by":"crossref","first-page":"10415","DOI":"10.3390\/ijms231810415","article-title":"TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma","volume":"23","author":"Liang","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.bcp.2026.118158_b0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijfoodmicro.2018.01.005","article-title":"Genomic and metabolic characterization of spoilage-associated Pseudomonas species","volume":"268","author":"Stanborough","year":"2018","journal-title":"Int. J. Food Microbiol."},{"key":"10.1016\/j.bcp.2026.118158_b0170","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s12602-024-10215-5","article-title":"Targeted Screening of Fiber Degrading Bacteria with Probiotic Function in Herbivore Feces","volume":"17","author":"Chen","year":"2024","journal-title":"Probiotics & Antimicro. Prot."},{"key":"10.1016\/j.bcp.2026.118158_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2003782","article-title":"Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of \u03b2-oxidation","volume":"16","author":"Yao","year":"2018","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bcp.2026.118158_b0180","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cmet.2018.06.001","article-title":"Etomoxir Inhibits Macrophage Polarization by Disrupting CoA Homeostasis","volume":"28","author":"Divakaruni","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118158_b0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-24676-6","article-title":"The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations","volume":"8","author":"O\u2019Connor","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118158_b0190","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/1878-0261.13112","article-title":"USP35 mitigates endoplasmic reticulum stress\u2010induced apoptosis by stabilizing RRBP1 in non\u2010small cell lung cancer","volume":"16","author":"Wang","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bcp.2026.118158_b0195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molimm.2025.05.001","article-title":"Knockdown of RRBP1 regulates endoplasmic reticulum stress to mitigate malignant progression and suppress bortezomib resistance of multiple myeloma cells by inhibiting GRP78 expression","volume":"183","author":"Wang","year":"2025","journal-title":"Mol. Immunol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:17:10Z","timestamp":1785071830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226004958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S0006295226004958"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118158","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RRBP1 promotes osimertinib resistance by activating fatty acid oxidation-dependent metabolic and immune reprogramming in EGFR-Mutant lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118158"}}